LEQEMBI Pen approved in Japan for early Alzheimer’s
Eisai and Biogen said Japan approved LEQEMBI Pen, the subcutaneous formulation of lecanemab, for early Alzheimer’s disease treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Eisai and Biogen announce Japan approval of LEQEMBI Pen
Eisai and Biogen said Japan approved “LEQEMBI Pen,” a subcutaneous formulation for early Alzheimer’s disease.